Galway, Ireland-based Aerogen’s proprietary vibrating mesh aerosol drug delivery technology will be used to deliver CanSinoBio’s recombinant novel coronavirus vaccine — Convidecia — under the development and commercial supply partnership. Commercial terms for the partnership were not disclosed.
The aerosolized vaccine from Tianjin, China-based CanSinoBio is directly inhaled through a cup dispenser in the patient’s airway. Aerogen said in a news release that the route mimics the natural infection pathway of the COVID-19 virus and may create additional benefits through generating mucosal immunity.
Aerogen touted interim results from Phase 3 clinical trials conducted by CanSinoBio that demonstrated an efficacy of 95.47% for preventing severe disease 14 days after a single-dose vaccination.
The company said inoculation through the inhaled aerosol route requires a smaller volume of vaccine to be used, providing the capacity to offer more access than would be possible with an injectable approach.
CanSinoBio is preparing an application for commercial authorization for its vaccine in China, with more clinical trials being prepared for other geographies.
“The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination,” Aerogen CEO & Founder John Power said in the release. “The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”
